Shannon T Kelley, General Counsel of Madrigal Pharmaceuticals, Inc., filed a Form 4 on November 6, 2026, disclosing the sale of 1,077 shares of common stock at $400 per share under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Shannon T Kelley, General Counsel of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
  • Transaction: 1,077 shares of common stock disposed of (transaction code S) on November 6, 2026
  • Sale price: $400 per share
  • Post-transaction ownership: 10,397 shares of common stock held directly following the reported transaction
  • 10b5-1 plan: The sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2026
  • Filing type: Filed by one reporting person; signed by Mardi Dier as Attorney-in-Fact on November 6, 2026

Kelley's Scheduled Share Sale Under 10b5-1 Plan at Madrigal Pharmaceuticals

According to the filing, Shannon T Kelley, serving as General Counsel of Madrigal Pharmaceuticals, Inc., disposed of 1,077 shares of the company's common stock on November 6, 2026, at a price of $400 per share. The transaction is coded "S," indicating a sale, and is recorded in Table I of the Form 4 as a direct disposition.

The filing states that "this sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2026." A Rule 10b5-1 plan allows corporate insiders to establish pre-scheduled trading arrangements at a time when they are not in possession of material nonpublic information. The Form 4 also bears a checked box confirming the transaction was made pursuant to such a plan. Following this transaction, the filing reports Kelley directly holds 10,397 shares of Madrigal Pharmaceuticals common stock.

No derivative securities transactions were reported in Table II of this filing. The Form 4 was signed by Mardi Dier as Attorney-in-Fact on November 6, 2026, and was filed by one reporting person. The issuer is identified in the filing as Madrigal Pharmaceuticals, Inc., with the ticker symbol MDGL on NASDAQ.

What Was Disclosed

Madrigal Pharmaceuticals General Counsel Shannon T Kelley disclosed the sale of 1,077 shares of common stock at $400 per share on November 6, 2026, under a Rule 10b5-1 plan adopted July 31, 2026, leaving Kelley with 10,397 directly held shares.